Olumiant Tablet, Film Coated
Product Images NDC 0002-4479

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Olumiant (NDC 0002-4479). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eli Lilly And Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Olumiant 1mg 30ct 066 02

Olumiant 1 mg (baricitinib) film-coated tablets label displaying the 30-count package from Eli Lilly and Company. The label includes the proprietary and generic names, dosage strength, quantity, and the Lilly logo. It also contains regulatory information such as Rx only status and storage instructions.*

FDA Label Image

Olumiant 2mg 30ct 034 02

Label for Olumiant (baricitinib) tablets 2 mg, oral film-coated tablets. The label indicates a package size of 30 tablets. It includes the Eli Lilly and Company logo and states 'Rx only' with instructions to always dispense with a medication guide. The label also provides storage instructions and warnings regarding tamper seals and child safety.*

FDA Label Image

Olumiant 4mg 30ct 073 00

Olumiant 4 mg film-coated tablets packaging label showing a bottle containing 30 tablets. The label includes the active ingredient baricitinib, prescribed only, and is manufactured by Eli Lilly and Company. It features dosage and storage instructions, a barcode, NDC number 0002-4479-30, and emphasizes dispensing with a medication guide.*

FDA Label Image

Structural Formula (Olumiant Uspi Chem V1)

Chemical structure diagram of baricitinib, the active ingredient in Olumiant. The diagram depicts the molecular arrangement of bars and rings characteristic of the compound.*

FDA Label Image

Olumiant Uspi F1 V3

A pharmacokinetic (PK) ratio chart showing AUC and Cmax ratios with 90% confidence intervals for various intrinsic factors relative to a reference for baricitinib (Olumiant). The chart includes factors such as weight, age, sex, race, renal and hepatic impairment, with dosage adjustment recommendations indicated for mild, moderate, and severe renal impairment.*

FDA Label Image

Figure 2 (Olumiant Uspi F2 V1)

A chart depicting pharmacokinetic (PK) ratios and 90% confidence intervals (CI) for coadministered drugs with baricitinib, including Methotrexate, Simvastatin, Ethinyl Estradiol, Levonorgestrel, and Digoxin. The x-axis shows the ratio relative to reference (0.0 to 2.0), with all ratios near 1.0, and recommendations indicating no dosage adjustments are needed for these drug interactions.*

FDA Label Image

Olumiant Uspi F3 V3

A forest plot chart displaying the pharmacokinetic interaction ratios and 90% confidence intervals for Olumiant (baricitinib) coadministered with various drugs. The chart shows ratios for AUC and Cmax relative to reference, with recommendations such as no dose adjustment for most drugs and half recommended dose with probenecid. Drugs evaluated include ketoconazole, fluconazole, rifampicin, probenecid, simulated ibuprofen and diclofenac, methotrexate, cyclosporine, and omeprazole.*

FDA Label Image

Olumiant Uspi F4 V2

A line graph comparing the percent responders over 24 weeks between Olumiant 2 mg (baricitinib) and placebo groups. The y-axis shows percent responders from 0 to 100%, and the x-axis shows weeks from 0 to 24. Olumiant 2 mg shows a higher and increasing percentage of responders compared to placebo throughout the study period.*

FDA Label Image

Olumiant Uspi F5 V1

Two line graphs labeled Trial AA-1 and Trial AA-2 depict percent responders over 36 weeks comparing placebo, Olumiant 2 mg, and Olumiant 4 mg. The y-axis represents percent responders and the x-axis represents weeks. Both trials show an increase in responders for Olumiant 2 mg and 4 mg over time, with the 4 mg dose showing the highest responder percentage, while placebo remains low and nearly flat throughout.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.